US12606631B2 - ETAR Antibodies, Patent Grant

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

USPTO granted Patent US12606631B2 to REMD Biotherapeutics Inc for isolated antibodies that specifically bind endothelin A receptor (ETAR). The antibodies have high affinity for ETAR, block ET-1 binding to ETAR, exhibit reduced immunogenicity, and have longer serum half-life compared to small molecule ETAR antagonists. Seven claims were allowed.